Terminated PHASE2 INTERVENTIONAL 1-arm NCT04044170

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

A Phase 2 Study of Poziotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Exon 20 Mutation in China and Korea

Sponsor: Hanmi Pharmaceutical Company Limited

Conditions NSCLC

Interventions Poziotinib

Updated 7 times since 2019 Last updated: Nov 16, 2020 Started: Jul 30, 2019 Primary completion: Apr 13, 2020 Completion: Apr 13, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study termination by the Sponsor

Other terminated trials from Hanmi Pharmaceutical Company Limited

More terminations from Hanmi Pharmaceutical Company Limited

Other NSCLC trials with similar outcome

Browse all NSCLC trials

Listed as NCT04044170, this PHASE2 trial focuses on NSCLC and remains terminated or withdrawn. Sponsored by Hanmi Pharmaceutical Company Limited, it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2020 — Jan 2021 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated

▶ Show 2 earlier versions

Sep 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2019 — Sep 2020 [monthly]

Recruiting PHASE2

First recorded

Jul 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hanmi Pharmaceutical Company Limited

Data source: Hanmi Pharmaceutical Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Cheongju-si, South Korea , Fuzhou, China , Guangzhou, China , Gyeonggi-do, South Korea , Hangzhou, China , Hefei, China and 5 more locations